TY - JOUR
T1 - Characterization of Cardiac Sympathetic Nervous System and Inflammatory Activation in HFpEF Patients
AU - Kaye, David M.
AU - Nanayakkara, Shane
AU - Wang, Bing
AU - Shihata, Waled
AU - Marques, Francine Z.
AU - Esler, Murray
AU - Lambert, Gavin
AU - Mariani, Justin
N1 - Funding Information:
This work was supported by a National Health & Medical Research Council (NHMRC) of Australia Fellowship support to Dr Kaye. Dr Marques is supported by a National Heart Foundation Future Leader Fellowship and National Heart Foundation Grants. The Baker Heart & Diabetes Institute is supported in part by the Victorian Government's Operational Infrastructure Support Program. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2022 The Authors
PY - 2022/2
Y1 - 2022/2
N2 - We have shown that systemic and cardiac sympathetic activation is present in heart failure with preserved ejection fraction (HFpEF) patients. Conversely, whereas systemic inflammatory activation was also detected in HFpEF, we did not detect local myocardial release of inflammatory cytokines. Activation of the sympathetic system correlated with both hemodynamic and demographic factors that characteristically cluster together in HFpEF. Together these data suggest that there may be a role for antiadrenergic therapies in certain HFpEF patients. The study does not implicate locally derived cytokines in the myocardial biology of HFpEF, although systemic sources may contribute to the global pathophysiology of HFpEF.
AB - We have shown that systemic and cardiac sympathetic activation is present in heart failure with preserved ejection fraction (HFpEF) patients. Conversely, whereas systemic inflammatory activation was also detected in HFpEF, we did not detect local myocardial release of inflammatory cytokines. Activation of the sympathetic system correlated with both hemodynamic and demographic factors that characteristically cluster together in HFpEF. Together these data suggest that there may be a role for antiadrenergic therapies in certain HFpEF patients. The study does not implicate locally derived cytokines in the myocardial biology of HFpEF, although systemic sources may contribute to the global pathophysiology of HFpEF.
KW - cytokines
KW - heart failure with preserved ejection fraction
KW - sympathetic nervous system
KW - transcardiac biomarker gradient
UR - http://www.scopus.com/inward/record.url?scp=85124464613&partnerID=8YFLogxK
U2 - 10.1016/j.jacbts.2021.11.007
DO - 10.1016/j.jacbts.2021.11.007
M3 - Article
C2 - 35257038
AN - SCOPUS:85124464613
SN - 2452-302X
VL - 7
SP - 116
EP - 127
JO - JACC: Basic to Translational Science
JF - JACC: Basic to Translational Science
IS - 2
ER -